Roxbury Financial’s Revolution Medicines RVMD Stock Holding History

Roxbury Financial’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$23.8K	Hold	116	–	–	0.02%	268
2026 Q2	$21.7K	Buy	+116	New	+$16.9K	0.02%	259

Other funds holding RVMD

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return

Roxbury Financial's RVMD Position: Q3 2026 in Review

Roxbury Financial held its Revolution Medicines (RVMD) position steady in Q3 2026 at 116 shares worth $23.8K. The position accounts for 0.02% of the portfolio, ranked #268.

Roxbury Financial first reported a position in RVMD in Q2 2026 and has held it in 2 quarters since. 577 funds tracked by Wall St. Rank hold RVMD as of Q3 2026.

Roxbury Financial held 116 shares of Revolution Medicines worth $23.8K as of Q3 2026.
Roxbury Financial left its Revolution Medicines share count unchanged in Q3 2026.
Revolution Medicines made up 0.02% of Roxbury Financial's portfolio in Q3 2026, its #268 holding.
Roxbury Financial first reported a position in Revolution Medicines in Q2 2026 and has held it in 2 quarters since.
577 funds tracked by Wall St. Rank held Revolution Medicines as of Q3 2026.

Based on Roxbury Financial's 13F filing for Q3 2026, filed 1 Oct 2026.